CJC-1295 and Ipamorelin: Why the Pairing Exists and What the Vial Math Looks Like

CJC-1295 and ipamorelin are paired because they act on two different receptors. CJC-1295 is a GHRH analogue working through the GHRH receptor; ipamorelin works through the ghrelin receptor. The rationale is complementary stimulation, not more of the same signal.

One detail decides almost everything about how a blend behaves, and most product listings mention it only in passing: whether the CJC-1295 includes DAC.

The DAC distinction

DAC stands for Drug Affinity Complex — a modification that binds the peptide to albumin in the bloodstream, dramatically extending how long it circulates.

Blends sold for research overwhelmingly use the no-DAC form precisely because the short half-life matches ipamorelin's. If a vendor cannot tell you which one you are buying, that is information about the vendor.

Why the pairing is proposed

The two receptors sit on different pathways into the same output. CJC-1295 increases the amplitude of GH pulses through the GHRH pathway; ipamorelin prompts release through the ghrelin pathway while — per the research on its selectivity — avoiding the cortisol and prolactin rises of older secretagogues.

The mechanistic rationale is coherent. What does not exist is a controlled human trial showing the combination outperforms either component alone, and that gap should be stated plainly rather than glossed over.

What the human evidence actually shows

This pairing has better human grounding than most combinations discussed in research communities, which makes it worth being precise about where that grounding stops.

CJC-1295 has been studied in people. A study in normal adult subjects found that the long-acting GHRH analogue activated the GH/IGF-1 axis and produced measurable changes in the serum protein profile (Sackmann-Sala 2009). Related GHRH analogues have full regulatory files: tesamorelin is FDA-approved for HIV-associated lipodystrophy, and sermorelin was formerly approved as a diagnostic and paediatric growth product. The class does what it claims to the hormone.

The problem is what that establishes. Growth hormone elevation is an intermediate, not an outcome. A compound can reliably raise GH and IGF-1 and still not deliver the things this combination is stacked for — better body composition, faster injury recovery, improved sleep, slower ageing. Those are separate claims requiring separate evidence, and for this pairing in healthy adults it does not exist. Recent reviews of GH-IGF1-axis peptides frame the issue exactly this way: a widening gap between the clinical evidence base and the way these compounds are self-administered (Dominikowski 2026; Tewari 2026).

There is also a trade-off that rarely appears on product pages. Sustained GH elevation reduces insulin sensitivity — a well-characterised effect of the hormone, not a fringe concern. For a combination frequently used for metabolic goals, that runs in the opposite direction to the stated intent.

What the evidence does not show

• No trial of the combination. Nothing compares CJC-1295 plus ipamorelin against either alone, or against placebo.

• No outcome data in healthy adults. Raising GH is demonstrated; that it produces the sought-after results is not.

• No established dose for either compound outside a research setting.

Combinations built around the GH axis, each with an explicit evidence grade, are catalogued in the peptide stacks directory.

Blend vial math

Blends are usually labelled as a combined total, which creates the same ambiguity as any blended vial: is a "10 mg blend" 5 mg of each, or 10 mg of each? Resolve that before adding water.

A 2 mg CJC-1295 + 5 mg ipamorelin vial

The constraint of any blend applies here too: a single draw delivers both in a fixed ratio, set by the vendor rather than by you. Separate vials cost more but allow each component to vary independently. The peptide calculator supports per-component concentrations for blend vials, and the BPC-157 and TB-500 guide works through the same labelling trap in more detail.

Reported effects, safety and anti-doping status

The GH secretagogues have a better-characterised effect profile than most research peptides, because the hormone they act on is itself well studied.

What is reported most often is consistent with raised GH: water retention, transient tingling or numbness in the hands, joint aches, and a flushing sensation shortly after administration. Ipamorelin's selling point within its class is what it avoids — it produces comparatively little cortisol or prolactin elevation, and less appetite stimulation, than earlier secretagogues such as GHRP-6.

The systemic consideration is insulin sensitivity, described above. Anything that sustains GH elevation moves glucose handling in an unfavourable direction, which matters more the longer a protocol runs and more still for anyone with existing metabolic risk.

Both compounds are prohibited under the World Anti-Doping Code, as growth hormone secretagogues, in and out of competition. For a tested athlete that is the operative fact (Villegas Meza 2026).

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Why are CJC-1295 and ipamorelin used together?

Because they raise growth hormone through two different receptors — CJC-1295 through the GHRH receptor, ipamorelin through the ghrelin receptor — so the effect is additive rather than redundant. That the resulting GH rise produces the outcomes the pairing is used for has not been demonstrated.

Is Mod GRF 1-29 the same as CJC-1295 without DAC?

Yes — the names are used interchangeably for the same modified GHRH fragment. Listings may use either.

Which form should a blend contain?

Blends overwhelmingly use the no-DAC form, because its roughly 30-minute action matches ipamorelin's short window. A DAC version circulating for a week alongside a compound acting over minutes is a different proposition entirely.

Why do half-life figures differ so much between sources?

Because the two forms are constantly conflated. A source quoting days is describing the DAC version; one quoting minutes is describing the no-DAC version. Both can be correct about different molecules.

Does raising growth hormone actually help?

It depends entirely on the goal, and for most goals this pairing is used for the answer is not established. GH elevation is measurable and reproducible; improved body composition, recovery or sleep in healthy adults from secretagogue use is not demonstrated. Sustained GH elevation also reduces insulin sensitivity.

Does the blend need refrigeration?

Once reconstituted, yes — 2–8 °C, never frozen, bounded by the shorter of peptide stability and the 28-day bacteriostatic water limit. See the bacteriostatic water guide.